

Supplementary Table S2. Relationship between *KIT* mutation and clinicopathological characteristics in 100 GIST patients

	KIT, n (%)		p-value ^a
	Mutation	Wild-type	
Histology			.322
Spindle	54 (72)	21 (28.0)	
Epithelioid	7 (53.8)	6 (46.2)	
Mixed	7 (58.3)	5 (41.7)	
Mitotic rate (per 50 HPFs)			.150
≤5	41 (75.9)	13 (24.1)	
6–10	9 (52.9)	8 (47.1)	
>10	18 (62.1)	11 (37.9)	
Tumor size (cm)			.425
0–5	23 (60.5)	15 (39.5)	
>5–10	24 (70.6)	10 (29.4)	
>10	21 (75)	7 (25.0)	
Risk stratification			.405
Very low/low risk	20 (64.5)	11 (35.5)	
Intermediate risk	19 (79.2)	5 (20.8)	
High risk	29 (64.4)	16 (35.6)	
Tumor necrosis			.519
No	19 (73.1)	7 (26.9)	
Yes	49 (66.2)	25 (33.8)	
Stage ^b			.675
Localized	29 (65.9)	15 (34.1)	
Locally advanced	26 (70.3)	11(29.7)	

GIST, gastrointestinal stromal tumor; HPFs, high-power fields.

^aChi-square test; ^b19 GIST patients were excluded from the analysis as they were missing tumor stage information.